基于中国诊疗现状的《NCCN指南:原发性皮肤淋巴瘤(2024年第1版)》解读

Interpretation of NCCN Clinical Practice Guidelines for Primary Cutaneous Lymphomas(Version 1.2024)Based on the Current Diagnosis and Treatment Status of China

原发性皮肤淋巴瘤是一组异质性疾病,具有独特的临床表现及组织学特征,部分亚型的诊断与治疗存在挑战。2023年12月美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)更新发布了《NCCN指南:原发性皮肤淋巴瘤(2024年第1版)》,与2023年版指南比较,此次更新主要集中于诊断评估原则、分期标准、不同分期蕈样肉芽肿的治疗原则及对放疗的建议等方面。本文结合我国原发性皮肤淋巴瘤的诊疗现状及特点,对该指南的主要推荐内容进行解读,以促进其在我国临床实践中的应用。

Primary cutaneous lymphomas are a group of non⁃Hodgkins lymphomas originating from the skin,with unique clinical and histological features.In December 2023,the National Comprehensive Cancer Network(NCCN)updated and released the Clinical Practice Guidelines for Primary Cutaneous Lymphomas(Version 1.2024).Compared to the 2023 edition of the Guidelines,this update mainly focuses on the principles of diagnostic assessment,staging criteria,treatment principles for mycosis fungoides(MF)at different stages,and recommendations for radiotherapy.In conjunction with the current situation and characteristics of the diagnosis and treatment of primary cutaneous lymphoma in our country,this article interprets the main recommendations of the Guidelines to promote the application of clinical practices in our country.